Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 4/20 | 0.65 |
| ▸ | QPCTL | Q9NXS2 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3102063 | 0.89 | QPCT (0.65) | QPCTQPCTLSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL7035206 | 0.86 | QPCT (0.67) | QPCTQPCTLSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL23123295 | 0.84 | QPCT (0.58) | QPCTQPCTLSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL13508672 | 0.82 | KCNH2 (0.62) | QPCTQPCTLSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3761479 | 0.81 | CYP11B1 (0.66) | SMN1; SMN2MAPTALDH1A1HSD17B10FGFR1 | |
| SCHEMBL13508796 | 0.81 | QPCT (0.56) | QPCTQPCTLSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL15579167 | 0.81 | KCNH2 (0.72) | QPCTQPCTLSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL6047768 | 0.81 | CYP11B1 (0.60) | QPCTQPCTLSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL12771538 | 0.80 | HTT (0.72) | QPCTQPCTLSMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL30138392 | 0.80 | HTT (0.72) | QPCTQPCTLSMN1; SMN2ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424859-B1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8772480-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | AMGEN INC. (US) | 2013-03-28 | — | — | US | disclosed |
| EP-2560953-A2 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-8362241-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2424859-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | Amgen, Inc (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126895-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20030181730-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-09-25 | — | — | US | disclosed |
| US-20030022927-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-01-30 | — | — | US | disclosed |
| US-6495583-B1 | DRUG FOR TREATING AN ALPHA-2 ADRENERGIC RECEPTOR ASSOCIATED DISORDER, NASAL CONGENSTION AND ALLEVIATING PAIN | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-17 | — | — | US | disclosed |
| US-6436982-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-08-20 | — | — | US | disclosed |
| US-20020072536-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-13 | — | — | US | disclosed |
| US-6403626-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20020065307-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-05-30 | — | — | US | disclosed |
| US-6316637-B1 | SELECTIVE FOR CLONED HUMAN ALPHA 2 RECEPTORS AND ARE USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-11-13 | — | — | US | disclosed |
| EP-0775134-A4 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMA CORP (US) | 1997-08-13 | — | — | EP | disclosed |
| EP-0775134-A1 | Imidazolin-2-ylaminobenzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004270-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | MTOR, PIK3CA, PIK3CD | QPCT 3189/4885QPCTL 4534/4885SMN1; SMN2 1834/4885 |
| US-20020065307-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | QPCT 2760/4885QPCTL 3955/4885SMN1; SMN2 2203/4885 |
| US-20020072536-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | QPCT 2599/4885QPCTL 3846/4885SMN1; SMN2 2392/4885 |
| US-20030022927-A1 | Novel benzimidazole derivatives | OPRL1, OPRD1, OPRM1 | QPCT 2997/4885QPCTL 4015/4885SMN1; SMN2 2343/4885 |
| US-20030181730-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | QPCT 2760/4885QPCTL 3955/4885SMN1; SMN2 2203/4885 |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | MTOR, PIK3CA, PIK3CD | QPCT 3189/4885QPCTL 4534/4885SMN1; SMN2 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.